Investigation of Dermatologic Toxicity from Immune Checkpoint Blockade in Advanced Malignancies
Advanced malignancies are increasingly being treated with immune checkpoint inhibitors, which can lead to immune-related adverse events (irAEs), including those in the skin. This project will investigate key clinical, pathologic, and immunologic details that will allow for improved classification of these cutaneous irAEs. Treatment of these toxicities will also be studied, allowing for the creation of more personalized and specific guidelines for therapy.
— Steven Chen, M.D., M.P.H.
- Harvard Medical School/Massachusetts General Hospital
- Medical Dermatology Career Development Award
Exploring Gene Expression Patterns and Biomarkers of Disease Severity in Central Centrifugal Cicatricial Alopecia
Central centrifugal cicatricial alopecia (CCCA), which has been associated with uterine fibroids, is unlike other scarring alopecias because fibrosis rather…
Characterizing the Microbiome in Postmenopausal Women with Vulvar Lichen Sclerosus
Vulvar lichen sclerosus is a chronic inflammatory condition that leads to scarring, obliteration of normal vulvar architecture, dyspareunia, and significant…
Cell Signaling Changes Induced by Surgical Debulking May Improve Response to Smoothened Inhibitor Therapy
Smoothened (SMO) inhibitors, such as vismodegib, are effective treatments for locally advanced basal cell carcinomas (BCCs). However, recurrences are frequent…